With projections that over the next 4-5 years almost half of drug discovery will be outsourced, biopharma companies are working hard to find the right partner to deliver comprehensive PK/PD and ADME support. With ever-growing pressure to deliver more data with fewer resources, that search may include ADME service providers based in low cost regions such as China or India. While the initial pricing considerations may be appealing, our customers often recount that there are significant advantages to choosing a more local partner. IQVIA Laboratories offers complete bioanalytical and ADME solutions for testing around the globe and across the product development spectrum.
Download this insight brief to learn about key factors to consider when thinking about offshoring your ADME screening services.
Author:
Shelby Anderson, Ph.D.
Complete the form below to access this insight brief
Related Insights
ADME Services
Accelerating your drug discovery, preclinical and clinical programs
Developing Assays for Novel Drugs
Current science regarding hybrid assays, why they are considered the next "big thing," the technical challenges, and the regulatory impact of these assays.
Hybrid Assays for Protein Bioanalysis
Combining immuno-affinity with liquid chromatography-mass spectrometry (LC-MS)
Absolute Bioavailability Analysis Using Stable Isotopes
A Liquid Chromatography-Tandem Mass Spectrometry Approach
Bioanalysis for Immuno Oncology with Mike Brown
I-O clinical development podcast series
High Throughput ADME Testing
Minimizing turnaround time for ADME assays
Bioanalytical & ADME Laboratory Services
Accelerate and enhance your discovery, preclinical and clinical programs
ADME Services
Accelerating your drug discovery, preclinical and clinical programs with ADME services
Assay Development for Large-Scale Clinical Studies
Bioanalytical expertise to support large-scale, international studies
Early Hit-to-Lead ADME Screening Bundle
Bundled Screening Assays to Accelerate Candidate Selection in Drug Discovery
